Jun Yoon - 01 Mar 2025 Form 4 Insider Report for Structure Therapeutics Inc. (GPCR)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
03 Jul 2025, 17:15:08 UTC
Prior SEC filing
20 Mar 2024
Next SEC filing
18 Mar 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Jun Yoon

Key filing fact

Jun Yoon filed Form 4 for Structure Therapeutics Inc. (GPCR) on 03 Jul 2025.

Key facts

  • This page summarizes Jun Yoon's Form 4 filing for Structure Therapeutics Inc. (GPCR).
  • 4 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 03 Jul 2025, 17:15.

Change

  • Previous filing in this sequence was filed on 20 Mar 2024.
  • Current net transaction value: -$95,489.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001962414 Primary reporting owner

Yoon Jun

Relationship
CHIEF FINANCIAL OFFICER
Address
C/O STRUCTURE THERAPEUTICS INC., 601 GATEWAY BLVD., SUITE 900, SOUTH SAN FRANCISCO
Signature
/s/ Jun Yoon
Signature date
03 Jul 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

GPCR transaction

Ordinary Shares

Tax liability

Transaction value
$47,025
Shares
-5,940
Change %
-0.46%
Price
$7.92
Shares after
1,287,359
Date
01 Mar 2025
Ownership
Direct
Footnotes
F1, F2
GPCR transaction

Ordinary Shares

Award

Transaction value
$0
Shares
+39,606
Change %
+3.1%
Price
$0.000000
Shares after
1,326,965
Date
01 Jul 2025
Ownership
Direct
Footnotes
F1, F3
GPCR transaction

Ordinary Shares

Tax liability

Transaction value
$48,465
Shares
-7,089
Change %
-0.53%
Price
$6.84
Shares after
1,319,876
Date
01 Jul 2025
Ownership
Direct
Footnotes
F1, F2
GPCR holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
1,554,586
Date
01 Mar 2025
Ownership
See footnote
Footnotes
F1, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

GPCR transaction Derivative

American Depositary Shares

Award

Transaction value
$0
Shares
+831
Change %
+39%
Price
$0.000000
Shares after
2,946
Date
21 May 2025
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount
2,963
Exercise price
Footnotes
F1, F5
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer.

Footnote F2

Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a restricted share unit award.

Footnote F3

On March 15, 2024, the reporting person was granted performance-vesting restricted share units ("PSUs"), each of which represents a contingent right to receive one Ordinary Share of the Issuer, which vest upon satisfaction of certain performance criteria. Certain of the performance criteria was determined to have been met effective July 1, 2025. The shares subject to the PSUs vest as follows: 50% of the shares vested on July 1, 2025 and the remainder will vest on January 1, 2027 subject to the reporting person's Continuous Service (as defined in the Structure Therapeutics Inc. 2023 Equity Incentive Plan) through such vesting date.

Footnote F4

By Jun Sik Yoon and Hayung Yang Yoon, Trustees of The Yoon Family Trust, dated December 11, 2019.

Footnote F5

Each ADS is convertible at any time, at the holder's election, into three Ordinary Shares of the Issuer. The ADSs have no expiration date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .